JP2017533201A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533201A5
JP2017533201A5 JP2017521564A JP2017521564A JP2017533201A5 JP 2017533201 A5 JP2017533201 A5 JP 2017533201A5 JP 2017521564 A JP2017521564 A JP 2017521564A JP 2017521564 A JP2017521564 A JP 2017521564A JP 2017533201 A5 JP2017533201 A5 JP 2017533201A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
drug
subject
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017521564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533201A (ja
JP6675394B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/056383 external-priority patent/WO2016064817A1/en
Publication of JP2017533201A publication Critical patent/JP2017533201A/ja
Publication of JP2017533201A5 publication Critical patent/JP2017533201A5/ja
Application granted granted Critical
Publication of JP6675394B2 publication Critical patent/JP6675394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017521564A 2014-10-22 2015-10-20 疾患及び障害の治療のためにインターロイキン−10を使用する方法 Active JP6675394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067337P 2014-10-22 2014-10-22
US62/067,337 2014-10-22
PCT/US2015/056383 WO2016064817A1 (en) 2014-10-22 2015-10-20 Methods of using interleukin-10 for treating diseases and disorders

Publications (3)

Publication Number Publication Date
JP2017533201A JP2017533201A (ja) 2017-11-09
JP2017533201A5 true JP2017533201A5 (enExample) 2018-11-29
JP6675394B2 JP6675394B2 (ja) 2020-04-01

Family

ID=55761394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017521564A Active JP6675394B2 (ja) 2014-10-22 2015-10-20 疾患及び障害の治療のためにインターロイキン−10を使用する方法

Country Status (11)

Country Link
US (2) US10143726B2 (enExample)
EP (1) EP3209320B1 (enExample)
JP (1) JP6675394B2 (enExample)
KR (1) KR20170084033A (enExample)
CN (1) CN107106655A (enExample)
AU (1) AU2015336101A1 (enExample)
CA (1) CA2963995A1 (enExample)
ES (1) ES2941234T3 (enExample)
MX (1) MX2017004983A (enExample)
WO (1) WO2016064817A1 (enExample)
ZA (1) ZA201702214B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP2616045B1 (en) 2010-09-15 2017-10-25 Randall J. Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
SI3139965T1 (sl) 2014-05-07 2022-01-31 Applied Molecular Transport Inc. Fuzijske molekule, izpeljane iz toksina cholix, za peroralno dostavljanje biološko aktivnega tovora
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
HK1248137A1 (zh) 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10
MX2018002298A (es) 2015-08-25 2018-07-06 Armo Biosciences Inc Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
CN108697776A (zh) 2016-01-11 2018-10-23 阿尔莫生物科技股份有限公司 在产生抗原特异性cd8+t细胞中的白介素-10及其使用方法
IL282986B2 (en) 2018-11-07 2024-01-01 Applied Molecular Transport Inc Colics-derivative carriers for oral administration of heterologous cargo
PL3650037T3 (pl) 2018-11-07 2022-06-06 Applied Molecular Transport Inc. Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby
JP2022519586A (ja) * 2019-02-04 2022-03-24 ゼネティック バイオサイエンシーズ インコーポレイテッド 糖ポリシアル酸化治療用タンパク質を使用する方法
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1202840A (en) 1985-06-10 1986-04-08 Jonathan R. Kleinsasser Combination wet and dry feeder for animals
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5032396A (en) 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5156301A (en) 1990-12-17 1992-10-20 Imi Cornelius Inc. Constant ratio post-mix beverage dispensing valve
EP0567586B1 (en) 1991-01-16 1995-07-12 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
ATE116550T1 (de) 1991-01-16 1995-01-15 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994017773A2 (en) 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
WO1994022473A1 (en) 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
CA2168110A1 (en) 1993-07-26 1995-02-02 Chuan-Chu Chou Agonists and antagonists of human interleukin-10
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PL175343B1 (pl) 1994-01-20 1998-12-31 Schering Corp Sposób pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej, kompozycja farmaceutyczna do pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej i kompozycja farmaceutyczna do leczenia nowotworów
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5770190A (en) 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5759859A (en) 1996-07-15 1998-06-02 United States Of America As Represented By The Secretary Of The Army Sensor and method for detecting trace underground energetic materials
US5945097A (en) 1996-09-06 1999-08-31 Schering Corporation Method for lowering cholesterol levels with interleukin-10
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
DK1053019T3 (da) 1998-01-07 2004-04-13 Debio Rech Pharma Sa Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
WO2000037096A2 (en) 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
WO2001005821A2 (en) 1999-07-16 2001-01-25 Maria Teresa Bejarano Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
EP1257574A1 (en) 2000-02-11 2002-11-20 Maxygen Aps Improved interleukin 10
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
AU2002307497A1 (en) 2001-04-23 2002-11-05 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
US20060127357A1 (en) 2002-11-29 2006-06-15 Roncarolo Maria G Rapamycin and il-10 for the treatment of immune diseases
WO2004056850A2 (en) 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
BR0317752A (pt) 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
JP4753867B2 (ja) 2003-04-15 2011-08-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ヒトil−18を含むコンジュゲートおよびその置換変異体
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005033307A1 (ja) 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
DE602004025509D1 (de) 2003-11-28 2010-03-25 Univ Sydney Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon
CN100467488C (zh) 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
CN1946742A (zh) 2004-03-11 2007-04-11 弗雷泽纽斯卡比德国有限公司 通过还原氨基化制备的羟烷基淀粉和蛋白质的偶联物
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
AU2005313492B2 (en) 2004-12-09 2011-12-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP1901769A2 (en) 2005-05-02 2008-03-26 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
WO2006130580A2 (en) 2005-05-31 2006-12-07 Avigen, Inc. Mutant il-10
WO2007003041A1 (en) 2005-07-01 2007-01-11 John Schrader Methods of isolating cells and generating monoclonal antibodies
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
SI1931704T1 (sl) 2005-10-04 2011-04-29 Zymogenetics L L C Priprava in čiščenje IL-29
WO2007061657A2 (en) 2005-11-14 2007-05-31 The Brigham & Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
AU2007314501B2 (en) * 2006-09-28 2013-05-23 Merck Sharp & Dohme Corp. Use of pegylated IL-10 to treat cancer
WO2008041953A2 (en) 2006-10-05 2008-04-10 Agency For Science, Technology And Research Dengue diagnosis and treatment
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
WO2008089491A2 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
WO2009036568A1 (en) 2007-09-19 2009-03-26 University Health Network Methods and compositions for treating tumors and viral infections
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR IMPROVING INFLAMMATION OF SN, PSYCHOSIS, DELI, PTSD OR PTSD
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
JP2011525616A (ja) * 2008-05-29 2011-09-22 ブリストル−マイヤーズ スクイブ カンパニー 共刺激経路の調節に対する患者応答を予測するための方法
WO2010022227A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
EP2379115B1 (en) 2008-12-17 2017-10-25 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
EP2488553B1 (en) 2009-10-12 2015-06-17 Pfizer Inc. Cancer treatment
WO2011051489A2 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
BR112012032206A2 (pt) 2010-06-16 2016-10-04 Abbvie Inc comparações de amostras de proteínas
KR101884654B1 (ko) 2010-07-09 2018-08-02 애피바디 에이비 폴리펩타이드
US8759617B2 (en) 2010-09-21 2014-06-24 National Institute Of Agrobiological Sciences Method for extraction and purification of recombinant proteins from transgenic plants
CA2813087C (en) 2010-09-28 2020-07-21 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
JP6121330B2 (ja) 2010-09-28 2017-04-26 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続時間が増した改変ポリペプチド
LT3757126T (lt) * 2010-11-05 2025-12-10 Novartis Ag Psoriazinio artrito gydymo būdas, panaudojant il-17 antagonistus
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
CN102145178B (zh) 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
WO2013130913A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
HK1215681A1 (zh) * 2013-04-18 2016-09-09 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
CA2908208A1 (en) 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
WO2015108785A1 (en) 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
US10293043B2 (en) * 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015369808A1 (en) 2014-12-23 2017-06-29 Armo Biosciences, Inc. Methods of improving yield in recombinant protein production
CN107405384A (zh) 2015-03-11 2017-11-28 尼克塔治疗公司 Il‑7部分与聚合物的缀合物
HK1248137A1 (zh) 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10

Similar Documents

Publication Publication Date Title
JP2017533201A5 (enExample)
RU2015149387A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2020203889A (ja) 抗体製剤
JP2016514132A5 (enExample)
JP2016537340A5 (enExample)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2015520188A5 (enExample)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2016530284A5 (enExample)
JP2019535651A5 (enExample)
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP2017512194A5 (enExample)
JP2017503014A5 (enExample)
FI3672631T3 (fi) Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia
EA200802350A3 (ru) Система доставки лекарств
RU2016114098A (ru) Новое производное аналога инсулина
ES2908141T3 (es) Formulaciones y dosis de cannabinoides
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JP2016505050A5 (enExample)
JP2018530525A5 (enExample)
JP2013520447A5 (enExample)
JP2018530612A5 (enExample)
JP2019501925A5 (enExample)